On World Atopic Eczema Day, Phlecs presents an innovative treatment approach aimed at addressing both the skin condition and the emotional well-being of patients.
Eczema (also known as atopic dermatitis) is a prevalent, chronic skin disorder characterized by symptoms such as dry skin, localized red scaly patches, intense itching, and skin discomfort. Its prevalence is substantial, affecting approximately 20% of children and up to 10% of adults. As of 2022, about 223 million people worldwide live with atopic dermatitis, with approximately 43 million of them being between the ages of one and four. The relentless itch often leads to frequent scratching, exacerbating skin damage and perpetuating a distressing cycle known as the “itch-scratch-itch” cycle. This condition’s burden can significantly impact an individual’s physical health, mental well-being, and overall quality of life.
Numerous clinical studies have been conducted on UV-free blue light therapy, demonstrating its safety, effectiveness, and gentleness in treating inflammatory skin conditions and alleviating itch without the adverse effects associated with medication or the risks posed by ultraviolet (UV) exposure. The Medical University of Łódź in Poland has undertaken clinical research involving 20 eczema patients who underwent 30-minute sessions of blue light therapy using Phlecs’ Full Body Blue Light device. The results of this study were presented at the International Congress of Atopic Dermatitis in Gdansk (August 30 – September 1 2023) and indicated significant improvements in patients’ conditions after just 10 treatments (data on file). On average, eczema symptoms, itching, and overall quality of life improved by 40% to 50%, reinforcing previous research findings. What’s novel is that blood sample analysis revealed a remarkable 96% increase in serotonin levels, which could potentially contribute to improved mood and mental health among patients.
David Aubert, CEO, and Co-founder of Phlecs, commented on these promising results, stating, “These findings are highly encouraging, and we anticipate further studies will confirm the long-term effectiveness and safety of blue light therapy. This marks the first time we’ve demonstrated that blue light may enhance serotonin production, providing insight into why patients find this treatment highly favorable. One of the current limitations of (UV-)phototherapy is that patients must visit a clinic for treatment, which can be time-consuming. To address this challenge, Phlecs is actively developing a new range of UV-free blue light home devices that will be introduced within the next few years. We are presently raising funds to support and accelerate our expansion.”
Phlecs is a Dutch startup founded by four former employees of PHILIPS, each with extensive experience in photo-dermatology. Over the past 15 years, comprehensive clinical research has been conducted on UV-free LED lighting for photo-dermatology treatments. At Phlecs, we firmly believe that blue LED light represents an effective tool for physicians and patients to manage the symptoms of itching and inflammatory skin conditions in a safe, effective, and cost-effective manner. Our first full-body professional device is CE certified class IIa and is currently available in Poland, Germany, and Denmark. We anticipate expanding our sales to other EU countries soon.
For more information: https://www.phlecs.com
Twenty-nine scale-ups developing diverse healthcare technologies have been selected to participate in the Bridgehead programme. Among them is Phlecs, the Dutch start-up that addresses unmet needs in dermatology with UV-free phototherapy solutions.
Out of 25 European competing projects, Phlecs has received the innovation award at the Ageing Fit Conference on the 2nd of March 2022 for its Full Body Blue Light device (https://www.ageingfit-event.com/2022-innovation-pitches/ ).”